Feasibility study of using the PREDICT kidney tool for patients with localised renal cell carcinoma
BJUI Compass · 2025-04 · 6 (4)
DOI: 10.1002/bco2.70014 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJUI Compass, online erschienen am 30.03.2025. Verfasst von Panayiotis Laouris und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Primary Care University of Cambridge Cambridge UK. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Cambridge Biomedical Research Centre, Medical Research Centre, National Institute for Health and Care Research.
Abstract (Originalsprache)
Background Localised renal cell carcinoma (RCC) is usually treated surgically, with post‐operative imaging‐based surveillance to monitor for recurrence. However, surveillance practices vary widely, and patients often lack a clear understanding of their risk of recurrence and follow‐up care. The PREDICT Kidney tool has been developed to enhance risk communication by providing individualised recurrence and mortality risk estimates. The tool uses the Leibovich score augmented with English national data to provide a personalised risk assessment of cancer recurrence and death from other causes, presented in both numerical and visual formats. Study Design A multicentre, prospective feasibility study of incorporating the PREDICT Kidney risk communication tool into the first follow‐up consultation for localised RCC patients post‐surgery. Endpoints Patient uptake into the study, completeness of data collection, consultation duration, the acceptability of the tool to both patients and clinicians, clinician adherence to the study “best‐practice” guide, variability in tool usage across clinicians and sites and patient‐level clinical outcomes including subjective and objective comprehension of risk of recurrence and follow‐up, perceived risk of cancer recurrence, risk conviction, satisfaction with the information provided on risk of recurrence and follow‐up, and fear of cancer recurrence. Patients and Methods We aim to recruit 60 patients from three hospitals in England and Scotland. Patients treated with surgery for primary localised clear‐cell RCC awaiting their first follow‐up appointment will be invited to take part. Participants will be allocated into two groups: standard care and standard care supplemented with the use of the PREDICT Kidney tool. Data will be collected through questionnaires, audio/video recordings of consultations and interviews with a subset of patients and clinicians. The study period is planned from September 2024 to July 2025. The findings will guide the design of a future randomised controlled trial to evaluate the tool's efficacy in clinical settings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Public Health and Primary Care University of Cambridge Cambridge UK.
- Department of Surgery University of Cambridge, Addenbrooke's Hospital Cambridge UK.
- Royal Free London NHS Foundation Trust, UCL Division of Surgery and Interventional Science London UK.
- Western General Hospital, NHS Lothian Edinburgh UK.
- The Institute of Genetics and Cancer The University of Edinburgh Edinburgh UK.
- Department of Oncology University of Cambridge, Addenbrooke's Hospital Cambridge UK.
ORCID-Profile: Chiara Re, Georgia Stimpson, James Blackmur, Alexander Laird, Grant D Stewart, Hannah Harrison, Juliet A Usher-Smith
Förderung
- NIHR Cambridge Biomedical Research Centre
- Medical Research Centre
- National Institute for Health and Care Research
- Mark Foundation For Cancer Research
- Cancer Research UK Cambridge Institute, University of Cambridge
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
Zitieren
APA
Laouris, P., Re, C., Stimpson, G., Bex, A., Blackmur, J., Laird, A., Batley, C., Stewart, G. D., Harrison, H., & Usher-Smith, J. A. (2025). Feasibility study of using the PREDICT kidney tool for patients with localised renal cell carcinoma. BJUI Compass, 6(4). https://doi.org/10.1002/bco2.70014
Vancouver
Laouris P, Re C, Stimpson G, Bex A, Blackmur J, Laird A, et al. Feasibility study of using the PREDICT kidney tool for patients with localised renal cell carcinoma. BJUI Compass. 2025;6(4). doi:10.1002/bco2.70014
BibTeX
@article{Laouris2025,
author = {Laouris, Panayiotis and Re, Chiara and Stimpson, Georgia and Bex, Axel and Blackmur, James and Laird, Alexander and Batley, Carley and Stewart, Grant D and Harrison, Hannah and Usher-Smith, Juliet A},
title = {Feasibility study of using the PREDICT kidney tool for patients with localised renal cell carcinoma},
journal = {BJUI Compass},
year = {2025},
volume = {6},
number = {4},
doi = {10.1002/bco2.70014}
}
EUVIMED